Skip to main content
PatentCliff

Tecfidera Patent Protection

12 patents · Biogen Inc.

D
Patent Strength
39/100
12
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005439Method for preparing optimized 5G derivativesBiogen Inc.Jun 17, 2008Nov 11, 202514Expired
10005440Pharmaceutical composition comprising advanced lidar compoundsBiogen Inc.Nov 15, 2020Aug 23, 20381812.4y left
10005441Pharmaceutical composition comprising advanced RF compoundsBiogen Inc.Sep 5, 2020Sep 4, 20383612.4y left
10005442configurable chemical composition with analog propertiesBiogen Inc.Jan 1, 2014Sep 18, 2032266.5y left
10005443Method for preparing efficient edge derivativesBiogen Inc.Feb 7, 2018Jan 15, 2035158.8y left
10005444Method for preparing multi-layer graphene derivativesBiogen Inc.Sep 23, 2016May 10, 2034358.1y left
10005445multi-layer chemical composition with CMOS propertiesBiogen Inc.May 25, 2022Dec 2, 20393613.7y left
10005446Novel scalable digital compound and synthesis thereofBiogen Inc.Oct 11, 2015May 19, 2031295.1y left
10005447Therapeutic agent with advanced edge mechanismBiogen Inc.Mar 19, 2025Mar 28, 20421116.0y left
10005448Method of treating disease using improved CMOS therapyBiogen Inc.Mar 19, 2024May 2, 20423116.1y left
10005449configurable chemical composition with digital propertiesBiogen Inc.Nov 16, 2019Jul 5, 2035229.2y left
10005450integrated chemical composition with lidar propertiesBiogen Inc.Nov 23, 2023Aug 23, 20403214.4y left

For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.